Hyaluronic acid-based drug delivery systems
US-2015250891-A1 · Sep 10, 2015 · US
US11045429B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11045429-B2 |
| Application number | US-201715412935-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 23, 2017 |
| Priority date | Sep 24, 2014 |
| Publication date | Jun 29, 2021 |
| Grant date | Jun 29, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Network materials which exhibit both shear thinning and self-healing properties are disclosed. The networks contain particles and gel-forming compounds. The networks are useful for a variety of biomedical uses, including drug delivery.
Opening claim text (preview).
We claim: 1. A shear-thinning injectable hydrogel comprising: one or more biocompatible gel-forming polymers selected from the group consisting of polysaccharides and proteins, optionally modified with one or more ester, carbonate, amide, carbamate, urea, ether or amine-linked capping groups, and nanoparticles having a diameter between 10 nm and 1000 nm formed of one or more biocompatible amphiphilic polymers comprising one or more hydrophobic polymers selected from the group consisting of polyanhydrides, poly(ortho)esters, polyesters, polyurethanes, and copolymers comprising the monomers of these polymers and one or more hydrophilic polymers selected from the group consisting of polysaccharides, proteins polyamino acids, polyalkylene oxides, optionally including an electrostatic charge enhancing agent, wherein the nanoparticles are non-covalently bound to multiple biocompatible gel-forming polymers to form the shear-thinning injectable hydrogel comprising between about 1 and 15 wt % nanoparticles in the shear-thinning injectable hydrogel, the hydrogel optionally comprising one or more therapeutic, prophylactic or diagnostic agents encapsulated within the nanoparticles, associated with the surface of the particles and/or dispersed through the hydrogel, wherein the dynamic shear viscosity of the shear-thinning injectable hydrogel at a shear rate within the range between 0.1 s −1 and 100 s −1 , inclusive, is greater than the sum of the dynamic shear viscosity of a suspension of the nanoparticles and a solution of the one or more biocompatible gel-forming polymers at the shear rate within the range between 0.1 s −1 and 100 s −1 , inclusive. 2. The shear-thinning injectable hydrogel of claim 1 , wherein the dynamic shear viscosity of the shear-thinning injectable hydrogel at a shear rate within the range between 0.1 s −1 and 100 s −1 is a multiplicative factor of between 2 and 100,000 times, inclusive, greater than the sum of the dynamic shear viscosity of the suspension of nanoparticles and the solution of the one or more biocompatible gel-forming polymers at the shear rate within the range between 0.1 s −1 and 100 s −1 , inclusive. 3. The shear-thinning injectable hydrogel of claim 2 , wherein the dynamic shear viscosity of the hydrogel at a shear rate within the range between 0.1 s −1 and 100 s −1 is a multiplicative factor of between 2 and 1,000 times, inclusive, greater than the sum of the dynamic shear viscosity of the suspension of nanoparticles and the solution of the one or more biocompatible gel-forming polymers at the shear rate within the range between 0.1 s −1 and 100 s −1 , inclusive. 4. The shear-thinning injectable hydrogel of claim 3 , wherein the dynamic shear viscosity of the hydrogel at a shear rate within the range between 0.1 s −1 and 100 s −1 is a multiplicative factor of between 10 and 1000 times, inclusive, greater than the sum of the dynamic shear viscosity of the suspension of nanoparticles and the solution of the one or more biocompatible gel-forming polymers at the shear rate within the range between 0.1 s −1 and 100 s −1 , inclusive. 5. The shear-thinning injectable hydrogel of claim 4 , wherein the dynamic shear viscosity of the shear-thinning injectable hydrogel at a shear rate within the range between 0.1 s −1 and 100 s −1 is a multiplicative factor of between 100 and 1000 times, inclusive, greater than the sum of the dynamic shear viscosity of the suspension of nanoparticles and the solution of the one or more biocompatible gel-forming polymers at the shear rate within the range between 0.1 s −1 and 100 s −1 , inclusive. 6. The shear-thinning injectable hydrogel of claim 1 , wherein at least one of the one or more biocompatible gel-forming polymers is a polysaccharide selected from the group consisting of celluloses, hyaluronic acids, dextrans, xanthans and combinations thereof. 7. The shear-thinning injectable hydrogel of claim 6 , wherein the polysaccharide is a cellulose or a modified cellulose. 8. The shear-thinning injectable hydrogel of claim 7 , wherein the cellulose is hydroxypropyl methylcellulose or carboxymethyl cellulose. 9. The shear-thinning injectable hydrogel of claim 1 , wherein the one or more biocompatible gel-forming polymers are modified with one or more ester, carbonate, amide, carbamate, urea, ether or amine-linked capping groups. 10. The shear-thinning injectable hydrogel of claim 9 , wherein the one or more capping groups are selected from the group consisting of C 1 -C 20 alkyl groups, C 3 -C 18 cycloalkyl groups, and C 6 -C 18 aryl, wherein any of the C 1 -C 20 alkyl groups, C 3 -C 18 cycloalkyl groups, and C 6 -C 18 aryl groups may be unsubstituted or substituted one or more times. 11. The shear-thinning injectable hydrogel of claim 1 , wherein the one or more biocompatible gel-forming polymers are at a concentration of between about 0.1 wt. % and about 10 wt. % prior to mixing with the nanoparticles. 12. The shear-thinning injectable hydrogel of claim 1 , wherein the one or more biocompatible amphiphilic polymers comprise one or more hydrophobic polymers selected from the group consisting of polymers of lactic acid and glycolic acid, poly(butic acid), poly(valeric acid), poly(caprolactone), poly(hydroxybutyrate), poly(ethylene-co-maleic anhydride), poly(ethylene maleic anhydride-co-L-dopamine), poly(ethylene maleic anhydride-co-phenylalanine), poly(ethylene maleic anhydride-co-tyrosine), poly(butadiene-co-maleic anhydride), poly(butadiene maleic anhydride-co-L-dopamine), poly(butadiene maleic anhydride-co-phenylalanine), poly(butadiene maleic anhydride-co-tyrosine), and copolymers comprising the monomers of these polymers. 13. The shear-thinning injectable hydrogel of claim 1 , wherein the nanoparticles comprise a core-shell nanoparticle. 14. The shear-thinning injectable hydrogel of claim 1 , wherein the one or more biocompatible amphiphilic polymers are a poly(alkylene oxide)-block-(polyester). 15. The shear-thinning injectable hydrogel of claim 1 , wherein the one or more biocompatible amphiphilic polymers are a poly(ethylene glycol)-block-poly(lactic acid). 16. The shear-thinning injectable hydrogel of claim 1 , wherein the one or more biocompatible gel-forming polymers are charged at physiological conditions. 17. The shear-thinning injectable hydrogel of claim 1 , wherein the one or more biocompatible gel-forming polymers are selected from the group consisting of hyaluronic acid, xanthan, and guar. 18. The shear-thinning injectable hydrogel of claim 17 , wherein at least one of the one or more biocompatible gel-forming polymers is hyaluronic acid. 19. The shear-thinning injectable hydrogel of claim 1 , wherein the one or more biocompatible gel-forming polymers are selected from the group consisting of aminopolysaccharides and positively charged proteins. 20. The shear-thinning injectable hydrogel of claim 1 , further comprising an ionic surfactant. 21. The shear-thinning injectable hydrogel of claim 20 , wherein the ionic surfactant is a cationic surfactant when the one or more biocompatible gel-forming polymers are negatively charged at physiological conditions. 22. The shear-thinning injectable hydrogel of claim 21 , wherein the cationic surfactant is selected from the group consisting of cetyltrimethylammonium bromide, cetyltrimethylammonium iodide, cetyltrimethylammonium fluoride, and cetyltrimethylammonium chloride. 23. The shear-thinning injectable hydrogel of claim 22 , wherein t
Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} · CPC title
Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates · CPC title
Cellulose; Derivatives thereof · CPC title
Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin · CPC title
Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.